A Drug-drug Interaction Study of Vorasidenib and a Combined Oral Contraceptive in Healthy Female Participants

Inclusion Criteria: * Healthy, nonpregnant, nonlactating pre- or post-menopausal female participants, including women of childbearing potential (WOCBP), assigned female at birth only. * 18 - 55 years of age (both inclusive) at Screening. * Body mass index (BMI) of 18.0 - 30.0 kg/m² (both inclusive) at Screening. * Body weight of at least 40 kg at Screening. * Participants of childbearing potential who must use two effective methods of birth control (e.g., non-hormonal intrauterine device \[IUD\], male or female condom with spermicide, cap, diaphragm, or sponge with spermicide), or abstinence, from Screening until at least 90 days after the last dose of vorasidenib or who must be surgically sterile (e.g., hysteroscopic sterilization, bilateral tubal salpingectomy, hysterectomy, or bilateral oophorectomy) at least 6 months prior to the first dose of IMP in the study. Participants of childbearing potential must have a negative serum pregnancy test at Screening and prior to the first dose of IMP in the study. * Post-menopausal participants (defined as amenorrhea for 12 consecutive months and documented plasma follicle stimulating hormone \[FSH\] level \> 40 IU/mL) who must have a FSH test confirming the post-menopausal status at Screening. * A continuous nonsmoker who has not used nicotine-containing products (e.g., snuff, nicotine patch, nicotine chewing gum, mock cigarettes, or inhalers) for at least 3 months prior to the first dose of IMP in the study based on a cotinine test…